Category Archives: Immunology

Hereditary angioedema

=C1 esterase inhibitor deficiency.  Acquired angioedema seen, esp ACE inhibitor associated acquired AE, more common in blacks and transplant patients.

Sense of smell is impaired in HAE, correlates with complement levels!

Angioedema is bradykinin mediated, hence why different from urticaria and not responsive to antihistamines, steroids etc.

Prothrombin fragment F1 and 2 plus D-dimer levels have diagnostic value in acute attacks.

Consensus algorithm in 2010 (more recent American viewpoints).

Clinical

Recurrent circumscribed, non-pruritic, non-pitting oedema. Not usually painful unless a pressure area. Can affect virtually anywhere but typically extremities.   Upper respiratory tract involvement eg tongue, pharynx and larynx accounts for the reported 15–33% mortality. Abdominal pain with vomiting are dominant symptoms in approximately 25% (intestinal wall and mesenteric oedema).

Urticaria is not a feature of C1 INH deficiency. However, prodromal “serpiginous” erythema has been reported in up to 25% of patients which may be mistaken for urticaria or even cellulitis.

Classically, oedema develops gradually over several hours, continues to progress slowly for 12–36 hr, and then subsides after 2–5 days. Sudden onset abdo pain without visible oedema can occur, with or without diarrhoea.

Attacks can be once a year in some, weekly in others.  Triggers are trauma including dental work, surgery; infection; emotional stress; drugs eg OCP, ACE inhibitors (which can cause oedema without HAE, of course).  Can present under 1yr of age.  Laryngeal attacks tend to come later in life (rarely under age 3).  Gets worse with puberty.

Good dental hygiene important in prevention!

Diagnosis

Testing under age 1 unreliable so always repeat.  Baseline C4 is low in 98% of cases so good screening test – if normal during attack then review diagnosis!  No need for CH50.

Low C1 inhibitor suggests type 1 HAE.  Acquired is possible in people over 40 without family history, C1q low in these cases.

If normal C1 inhibitor but strong clinical suspicion, do C1 inhibitor functional assay to look for type 2 HAE.  If still normal, repeat testing during attack.

Type 3 HAE has normal C1 inhibitor and function – mainly women.  Due to Factor XII gene mutations and others.

Genetic testing (SERPING1) may be useful where these tests not conclusive.

Acute attacks

Human pdC1-INH (Berniert, Cinryze else Conestat-alpha which comes from transgenic rabbits) is recommended for all attacks (for adults and children). Not licensed for acquired? Beware rabbit allergy!?

  • “Wait and see” is only an option for attacks not involving the face, neck, or abdomen and intestine.
  • Attenuated androgens no longer available – stanozolol (up to 16 mg/day) or danazol (up to 1 g/day) given early (may shorten its duration).
  • Tranexamic acid weak – needs to be taken immediately – most don’t bother now
  • Upper airway esp voice alteration and dysphagia – give C1 INH promptly. How easily can family find veins?? Else family bring to emergency department! Dose depends on weight and seriousness of reaction. In a life-threatening situation we recommend 1000–1500 U. In other situations 500–1000 U is often sufficient. Administering C1 INH concentrate shortens the duration of attacks by about a third and also halves the time to the beginning of the relief of symptoms.
  • For acute attacks of abdominal oedema, pain relief should be given at an appropriate level. Non-steroidal anti-inflammatory drugs are useful.
  • If the attack is severe, C1 INH concentrate should be infused at the same dose as above. Early intervention prevents avoidable pain and reduces disruption to the patient’s life. The patient should be observed closely until symptoms start to improve. The median time to the beginning of the relief of symptoms after concentrate infusion is 0.5–1.5 h, with complete resolution of symptoms after 24 hr. If symptoms persist at a high intensity 2 h after infusion, additional C1 INH concentrate should be given and alternative diagnoses should be considered.
  • No benefit from steroids or antihistamines!  Adrenaline has only a transient and modest effect.
  • Home therapy is recommended for children with frequent and debilitating attacks, under the condition of medically supervised training.
  • Recombinant C1-INH concentrate (Ruconest) similar.
  • Subcut bradykinin B2 receptor antagonist Icatibant safe, effective and convenient (subcut) for acute attacks. Less rapid onset but then you can do it yourself. Similar price. Theoretical risk of thrombosis

Short-term prophylaxis

Children don’t need prophylaxis as much as adults, but is recommended for surgery in the head and neck area. pdC1-INH is recommended, if not available, use danazol. Tranexamic acid can also be used.

Give C1-INH up to 24hrs before procedure (with/without further dose post-procedure), or else 48hr steroids/TA before and after.

Long-term prophylaxis

The only treatment option for long-term prophylaxis in children is pdC1-INH. Question is not just frequency of attacks but severity (laryngeal vs hand, for example).

Attenuated androgens worked but not available. Side effects not great, include weight gain, virilization, muslce cramps, jaundice. In children, stunts growth.

C1 inhibitor has short half life so needed every 2-3 days. Subcut works for prophylaxis! Costs £140K per year.

Berotralstat – oral kallikrein inhibitor – some GI upset, long QT. NICE/SMC approved. £10 000 per month so similar.

Lanadelumab – subcut monoclonal kallikrein inhibitor. 2-4 weekly. Similar cost.

At the current pediatric consensus meeting for German-speaking countries, several concerns were raised about these international consensus recommendations:

  • Experts strongly advocated taking body weight into account in treatment in pediatrics. Discomfort emerged as to whether appropriate dosing is possible for patients between 12 and 18 years of age with fixed doses established in adults.
  • For attenuated androgens, sufficient data are lacking on the long-term safety over decades of use Should there be a reason for its use in isolated cases, the initial dose (see above) should only be administered for a short period (e.g., for short-term prophylaxis prior to elective procedures).
  • Tranexamic acid (less effective than attenuated androgens) is recommended for long-term prophylaxis in patients for whom pdC1-INH is not available or in whom attenuated androgens are deemed unacceptable.  Side effects are nausea, vomiting, diarrhoea, muscle cramps. Thrombosis is theoretical risk, not seen in practice, in US restricted as evidence in animals of tumours, regular eye examination and LFTs recommended in BNF.

Autoimmune HAE can be treated with C1-INH but some are resistant due to rapid catabolism so icatibant seems a good option. HAE with normal C1-INH function do not respond to antihistamines or steroids but do respond to C1-INH, tranexamic acid, danazol.

[ Eur J Pediatr (2012) 171:1339–1348]

[Bowen et al. Allergy, Asthma & Clinical Immunology 2010, 6:24]

Prednisolone allergy

Both type I and type IV allergic reactions associated with corticosteroids have been reported in the literature.  Due to drug itself, the excipients making up the drug, or both?

Corticosteroids have been classified into 5 different categories based on their structural and chemical properties:

Group Agents
A Hydrocortisone

Methylprednisolone

Prednisolone

B Budesonide

Triamcinolone

C Betamethasone

Dexamethasone

D1 Mometasone furoate

Fluticasone propionate

Cross-reactivity outside of these groups has only really been seen with group D2, which includes only lesser known steroids eg hyrdocortisone 17 butyrate, and group A.  Budesonide has also been described to exhibit some cross-reactivity with group D2, due to a stereoisomer, rather than its group conformation.  There is also some cross-reactivity with sex hormones, although the clinical significance is unclear – there is a type of cyclical dermatitis which is thought to be related to endogenous progesterone sensitivity.

[Allergy. 2009 Jul;64(7):978-94. doi: 10.1111/j.1398-9995.2009.02038.x]

Oral allergy syndrome

Used interchangeably with Pollen food syndrome, although PFS is probably a better name because it is more specific and more closely represents what is going on. Only described in 1942!

Pollen Food Syndrome (PFS) refers to fruit and/or nut allergy, associated with birch pollen allergy (ie hayfever).  The food allergy part of the deal however is usually mild, eg itching/tingling/scratching/numbness, of lips/tongue/throat (sometimes ears) only, which distinguishes it from primary peanut or tree nut allergy. Peri-oral rash, nausea, abdo pain are sometimes reported. Mild angioedema of tongue and lips can occur, as can cough – you would be more nervous about assuming PFS in this situation, of course.

Peeling root vegetables is a trigger in those who have vegetable types of PFS! Another reason why PFS is a better name.

Extremely common – probably 40% of children with birch pollen related hay fever (and more than 70% of adults)! Getting more common too – climate change related hay fever season, and more allergenic pollen (thought to be related to ozone levels, hence cities can be worse)…

Due to cross reactions between birch pollen and similar proteins (most commonly PR-10 group – also oak, beech, alder) found in fruit, particularly those fruit with pips inside and a peel eg apple, pear, peach – this group of fruit is known as Rosaceae and includes nectarine, cherry, apricot, plum.

Other fruits involved include Kiwi, Mango, Melon, Tomato, Raspberry, Strawberry. Kiwi and banana still quite common primary allergies. Can be both, of course!

Peanut, Hazelnut and almond most common nuts involved in PFS in UK. 

Sometimes vegetables (Carrot, Celery, Potato, Asparagus, Pepper). Poppy seed, herbs and spices (Aniseed, Camomile, Coriander, Cumin, Fennel, Parsley).

Profilin group (Bet v2) about 20% of PFS in UK, more common in Southern Europe. Birch and oak too, but also olive tree, London plane, grasses (Phl p12), ragweed. Watermelon profilin cross reacts with melon, kiwi, peach.

There are other similar allergy syndromes including celery-spice-mugwort syndrome and latex allergy

You may find that you can eat the fruit if peeled, tinned, cooked or processed (eg jam). The ripeness, even the specific species, can matter too. Cold storage may increase the risk of reactions. Freezing doesn’t seem to make any difference.

Some affected individuals even put up with the itching because they prefer not to miss out on their favourite fruit!

Often emerges in later childhood or early adulthood, and only after hay fever develops. Seen in up to 25% of kids, but they don’t always recognise it themselves! Big variations geographically, obviously related to distribution of birch.

The main impetus for making the diagnosis is to select patients with a lower risk of anaphylaxis, even if nut allergic.  However, not always possible, and certainly not 100% reliable.  Thought that about 3% of PFS patients have systemic rather than just oral symptoms, and 1-2% will have anaphylaxis.  Potential confusion too because people who have primary IgE mediated peanut or nut allergy may of course also report isolated oral symptoms if low dose exposure.  In the original description of oral allergy syndrome, 50% progressed to systemic reactions!

So, important to differentiate –

  • primary IgE peanut or tree nut allergy who have only had oral symptoms so far (but are are risk of severe reactions, due to sensitisation to storage proteins, typically found in seed/kernel)
  • benign PFS, where allergic to Bet v 1, its homologues (eg Ara h 8, Cor a 1 – see peanut allergy) or other PR-10 or Profilin.  These proteins are usually in the pulp of the fruit. Soya (Gly m 4) is an exception where soya milk can cause severe reactions.
  • PFS with potential for systemic reactions where allergic to LTP (typically found in the peel)

BSACI peanut and tree nut allergy guidance is to go with typical history and only test if:

  • Atypical/severe reactions
  • reactions to processed rather than raw plants (including roast nuts)
  • Soya products other than soya milk
  • Tree nuts other than hazelnut, almond, walnut
  • Legumes other than peanut

BSACI guideline says beware younger children (under 8) with kiwi, melon or banana allergy, even if otherwise typical history – PFS unlikely.

Testing could be Prick to prick tests (important to get skin and pulp!), or else consider:

  • Pru p 3 for LTP allergy– if reacts to cooked food or other atypical features (even if not peach specifically!)
  • Gly m 4 if soya milk negative (PR-10 but can be severe reactions).  Gly m 5/6/8 if atypical
  • For hazelnut and almond, best to do prick to prick, for raw AND roast; if positive, do Cor a 1 (PR-10, so PFS) with 9 and 14 (which would suggest primary)
  • Ara h 2 if any standard tests for peanut positive (should be negative in PFS) – if negative, Ara h 1/3/6
  • Jug r 1 if walnut tests positive, Ber e 1 for brazil nut.

Oral challenges only possibly needed if avoiding multiple foods.

Pollen subcut immunotherapy does not seem to help PFS, unfortunately.  Insufficient evidence about pollen sublingual immunotherapy.  Some work around oral immunotherapy with fresh food or with isolated proteins.

The risk of anaphylaxis in PFS is quoted as 10%, but this is perhaps misleading as it usually relates to very high doses such as smoothies, tofu, soya milk. Other possible risk factors include:

  • severe seasonal asthma
  • Acid suppression therapy!
  • Jackfruit!

Adrenaline autoinjectors are rarely justified.

But there are reports of anaphylaxis to peanut despite being exclusively Ara h 8 sensitised and passing an oral challenge – but had big dose on empty stomach! [https://doi.org/10.1111/cea.12425]

Golden Delicious, Granny Smith and Cox’s the worst of the fruit, with the most Mal d 1 (Bet v 1 homologue).

BSACI does not mention whether prick to prick with frozen is effective, only that you can still react to frozen fruit/veg.

More severe reactions described with jackfruit! Beware smoothies, protein shakes, edamame beans!

Bean sprouts, mange tout and sugar snap mentioned specifically as usually only lightly cooked, or just raw.

[Isabel Skypala, BSACI PFS guidance, Clin Exp Allergy 2022]

Macrolide allergy

The majority of cases reported are non immediate reactions eg maculopapular rash, urticaria. The incidence of anaphylactic reactions is extremely low.

Less than 15% of those suspected of having macrolide allergy are finally confirmed as allergic, mainly by direct provocation testing.

Cross-reactivity between the different macrolides is variable and little information is available.

Current Opinion in Allergy and Clinical Immunology 14(4), August 2014, p 278–285. DOI: 10.1097/ACI.0000000000000069

Penicillin allergy

Children with pneumonia with a label of penicillin allergy were found to have:

  • higher risk of hospitalization (RR 1.15)
  • acute respiratory failure (RR 1.27)
  • and need for intensive care (RR 1.46; 95% CI, 1.15-1.84)
  • increased cutaneous drug reactions (RR 2.43)

[US Journal of Allergy & Clinical Immunology in Practice.  11(6):1899-1906.e2, 2023 Jun.]

Cephalosporins

Atanaskovic-Markovic et al found that cross-reactivity between cephalosporins and penicillins varied between 0.3 and 23.9%, being higher among penicillins and between first-generation and second-generation cephalosporins.

However, it has recently been shown that all penicillin allergic children can tolerate cefuroxime, presumably as it has a different side chain.

Cross-reactivity appears to be higher in immediate reactions, and when penicillins and cephalosporins are identical or similar in the R1 side chain, as happens with the first and second-generation cephalosporins.

Currently BNFc says to avoid cefalosporins if history of immediate penicillin hypersensitivity, but if use of cefalosporin is “essential” then can be used (but not cefalexin!).

Canadian study did oral challenges for non-blistering rashes – safe – but mostly cefprozil allergy (and linked to food allergies).

De-labelling

In hypothetical case of de-labelled patient, 47% of anaesthetists would not prescribe penicillin to patient anyway (n=5000)!

Primary care don’t always remove label even after de-labelling! (patient held records would help…)

Needs culture change in primary care and paeds of documenting reactions!

Make sure note is added to patient record when de-labelled. Electronic labels don’t necessarily help – not always possible to remove an allergy label from drug prescription system, depending on the system, may only allow subsequent note to be added.  Free text systems do not encourage accurate description!

Alabama trial from NIHR to report on RCT of de-labelling in primary care; SPACE study in secondary care (nurse/pharmacist delivered).

See Testing for antibiotic allergy.

Nasal flu vaccine

Live attenuated influenza vaccine (LAIV).  Now available in quadrivalent form, Fluenz Tetra in Europe, Flumist in US.  Transmission to another person has only ever been documented once, and it was asymptomatic!

The extra B hopefully makes it better than 2014/15 where poor coverage.  Live attenuated is more effective and has less systemic effects than injected vaccines.

Current annual programme in Scotland is for all 2-5yr olds to be offered vaccine by public health, whereas all primary and secondary school children will be offered vaccine at school.
Cut off for 2yr olds is age 2 on 1st September.
For infants between 6 months and 2, previous hospital admission for lower respiratory tract infection (which would include all our bronchiolitis babies!) is a clinical risk indicator, along with asthma, chronic heart/kidney/neuroresp disease, or indeed anything else where you thing getting flu is likely to exacerbate the underlying condition.

If you miss your school appointment, up to the family to request another via NHS Lanarkshire vaccine helpline 01698 687456.

Although GPs aren’t much involved anymore in vaccine programme, they should still offer it if a family prefers it, or if a family are keen to get it earlier than they might otherwise as part of the schools programme.

Most kids will be offered nasal live flu vaccine (Fluenz Tetra).  Contraindications to nasal flu vaccine are:

  • under 2yrs of age,
  • wheezing or extra bronchodilator within the previous 72 hours,
  • severe immunodeficiency (esp cellular) or immunosuppression eg leukaemia/lymphoma, high dose oral steroids
  • aspirin use (eg Kawasaki) – theoretical risk of Reyes [reported with wild type influenza and aspirin]

Kids on high dose inhaled steroids no longer require consultant approval to get nasal vaccine.

Kids previously in PICU for asthma, or who require regular oral steroids for asthma, require consultant approval to get nasal vaccine. Otherwise they should get injectable.

If you can’t have nasal, then should get injectable (inactivated) vaccine.  Can be given from age 6 months.

A second dose is needed after 4 weeks minimum if you are in a clinical risk group, and under 9yrs, and this is the first time you are getting flu vaccine.  This applies whether you get nasal or injectable flu vaccine.

For egg allergy, advice, as before, is that children with egg allergy – including those with previous anaphylaxis to egg – can be safely vaccinated with nasal vaccine in any setting (including primary care and schools). The only exception is for children who have required admission to intensive care for previous severe anaphylaxis to egg, who should be offered nasal flu vaccine in hospital [lack of data, not definite risk!].

If a kid with egg allergy has a contraindication to nasal flu vaccine (eg immunosuppressed) and needs injectable vaccine, then it should be either an egg free (cell based) injectable vaccine (the one from Seqirus is licensed from age 2) or low egg content (“split virion inactivated vaccine”), viz less than 0.12mcg/ml (equivalent to 0.06 µg for 0.5 ml dose).

NSAID hypersensitivity

Ibuprofen etc are a common cause of reactions, but mostly non immune mediated, via COX -1 inhibition. Previously called pseudo-allergy or intolerance, best called hypersensitivity, then subdivided into allergic or non-allergic. Often occurs in patients with underlying problem eg asthma, chronic urticaria, rhinosinusitis – exacerbates underlying condition. Hypersensitivity can be to a single drug, or cross-reactive, ie to unrelated drugs from different families (salicylates ie aspirin, propionic derivatives eg ibuprofen, acetic acid derivatives eg diclofenac, etc). Cross reactivity suggests a non-immune mechanism. Without history to support single drug (or family) hypersensitivity, you would have to advise the patient to avoid all NSAIDs.

Testing

  • Skin testing with culprit drug is appropriate if you have an acute urticarial or angioedema reaction in a single drug/family.
  • Oral challenge is appropriate to confirm all types of hypersensitivity, esp in equivocal histories. At the same time, challenge with aspirin to check cross-reactivity, and with next best alternative NSAID. Start 1/10 dose, increase every 2 hours.
  • For nasal/bronchial symptoms, inhaled lysine aspirin is safer and faster, but only 77-90% sensitive cf 90% for oral. Intranasal is equivalent if inhaled/oral not possible.
  • If patient is on long term steroids, or else has been well controlled for a long time, sensitivity seems less!
  • Consider proceeding to challenge with COX2 (coxib) if challenge positive.

Aspirin desensitization works for NSAID exacerbated respiratory disease, and NSAID induced (cross reactive) skin disease, controversial for chronic urticaria and no data for single drug skin disease or anaphylaxis. But needs maintenance dosing so only really useful for chronic conditions eg needing antiplatelet therapy.

Allergy 2013:68;1219

Kawasaki syndrome

A syndrome of unknown cause, characterised by persistent fever, conjunctivitis and mucosal changes eg strawberry tongue in a young child who has often been treated empirically with antibiotics without improvement, and is invariably miserable. Potentially complicated by coronary aneurysms, which may be fatal. Kawasaki’s is the leading cause of acquired heart disease globally after rheumatic fever, and is the leading cause in the North.

It is a vasculitis affecting medium sized arteries, and other arterial vessels down to capillary size. Second most common vasculitis in childhood, after IgA vasculitis.

Was thought to be a superantigen disorder, ie with no specific infectious agent, polyclonal B activation – coronary aneurysms have been seen in other superantigen diseases eg toxic shock, have also been reported in meningococcal septicaemia. But now thought to be conventional, but unknown, infectious trigger.

Similarities with COVID PIMS-TS.

Genetics important, risk higher in East Asian immigrants, plus family history, single nucelotide polymorphisms found in 6 genes including FcγR2a, caspase 3 (CASP3), and human leukocyte antigen class II.

Clustering has been shown (Knox test significant within the space-time interval of 3 km and 3-5 days) which suggests an infectious trigger [PIDJ 27(11):981-985, Nov 2008]. TNF alpha seems important, in an animal model, knock out mice or anti TNF treatment prevents aneurysm development.

The underlying pathology is a vasculitis, and although coronary disease is the best recognized there is increasing evidence that other medium sized arteries are affected with descriptions in the literature of peripheral gangrene and cerebral infarction. Proposed model includes necrotizing vasculitis, plus chronic/subacute vasculitis, 2 weeks after onset and sometimes lasting months, with a unique type of luminal myofibroblastic proliferation. 

Epidemiology

More common in males, peak age 18-24 months.

BPSU Kawasaki – 553 cases were notified: 389 had complete KD, 46 had atypical KD and 116 had incomplete KD!  Median time to IVIG in those with Coronary artery aneurysms (CAAs) was 10 days cf 7 days for those without.  Rate of CAA in under 1yr was 39%.  19% overall had CAA despite treatment.  Associated with low albumin, and incomplete.  Only 1.6% developed giant aneurysms, which have the worst prognosis, of course.

Risk of CAA estimated at 20-40% if untreated.  [Archives PMID 30104394]

Incidence in west seems to have plateaued, after decades of increase (?ascertainment bias). 10-20x higher rate in NE Asia (Japan, Taiwan, Korea), plus continues to increase! 1% of all Japanese kids will have had KD by age 10. But unrecognized before 1950, whereas pathological specimens in UK from over a 100yrs ago show same process.

Less complications in Asia!  Better diagnosis? Arguably all European cases could be considered high risk…

Japan has had 3 epidemics, the only country to have had them, but none since 1986.

Data from China and India indicate increase, with only a few case reports prior to 1990. Rate in Chandigarh equivalent to UK now, presumably underestimate, but already outnumbers rheumatic fever cases.  Also high rate in Kerala, but related to affluence or health care availability?    Rate in Shanghai approaching NE Asia rate. Rate in Hong Kong has tripled in 20 years. Will become the predominant cause of acquired cardiac disease?

Association between seasonal wind patterns in Pacific and KD rates in Japan, California and Hawaii! May relate to infectious agents.

[Singh S, et al. Arch Dis Child 2015;100:1084–1088. doi:10.1136/archdischild-2014-307536]

Case definition

(American Heart Association):

  • Fever of 5 days duration or more
  • plus 4 of the following (ie only drop 1):
    1. Conjunctivitis: Bilateral, bulbar, without exudate
    2. Lymphadenopathy: Cervical, >1.5 cm
    3. Rash: Polymorphous, no vesicles or crusts
    4. Changes of lips or oral mucosa: Red cracked lips; “strawberry” tongue; or diffuse erythema of oropharynx
    5. Changes of extremities:
      • Initial stage, erythema and oedema of palms and soles
      • Convalescent stage (about two weeks) periungual desquamation of fingers and toes
Images from Circulation journal 2017

These are all acute febrile stage symptoms, first 2 weeks (besides the desquamation) – but not necessarily all at the same time, sometimes only on history. After 2 weeks, persistent irritability, poor appetite, conjunctival injection. If still febrile at this point then high risk of cardiac complications. Any coronary artery ectasia or aneurysms may enlarge from week 4-8. Ectasia may resolve.

In Japan, prolonged fever is one of the optional features – 1/3 of Japanese children get IVIG before day 4! McCrindle guideline (AHA, 2017) suggests complete Kawasaki disease may be diagnosed with 4 days (possibly even 3 days) fever if one of the features is peripheral erythema/swelling.

Many people would also diagnose if only 3 of these features plus coronary artery aneurysms detected. Lymphadenopathy is the least common feature (?easy to miss) – esp uncommon in younger children. Perineal desquamation is also quite characteristic.

There may also be abdominal pain, diarrhoea, hepatitis/pancreatitis, arthralgia/arthritis, aseptic meningitis, facial nerve palsy and pneumonitis (with or without pulmonary nodules). There may be a murmur (mitral incompetence), and myocarditis can occur but it is rarely severe. CXR changes (nodules, peribronchial and interstitial infiltrates). Aortic root enlargement. Desquamation in groin. Hydrocoele and gall bladder hydrops! Anterior uveitis. Renal involvement, encephalopathy have been described, macrophage activation syndrome has been reported rarely.

Pitfalls –

  • infants, adolescents (“glandular fever”).
  • Signs change over time – rash fades, desquamates, then nail changes but similarly lymph nodes, mouth changes.  So at any one time only a few features may be evident – especially beyond first week.
  • Normal or low platelets (actually a high risk feature in some scoring systems)
  • Sterile pyuria (“UTI”), “aseptic meningitis”
  • Presentations with myocarditis, surgical abdomen (GI vasculitis)
  • Single dose of IVIG without response does not mean diagnosis is wrong, in fact means more aggressive treatment required.
  • Beware positive cultures putting you off diagnosis! Might be triggering infection! Even Strep, adenovirus

Tips –                           

  • BCG reactivation as a clue
  • Arthritis as a clue
  • Axillary/inguinal aneurysms on examination? [Janet G-M]
  • Repeat echo early, especially where diagnosis still not clear cut. Cardiology need chasing!?
  • IVIG raises ESR! Don’t interpret as treatment failure!
  • Incomplete/uncertain have highest risk of complications! So consider if fever >=5/7 with 2 criteria, or infants [only infants?] with fever >= 7/7 without necessarily any criteria, but no other explanation! CRP>30 and ESR>40 should trigger further assessment eg echo and use of additional lab criteria eg anaemia, high platelets (>450 beyond day 7, but also <140), high ALT, high WCC (>15), low albumin (<30) . Echo if CRP/ESR low but peeling. 3 or more additional lab criteria sufficient to make diagnosis.

Many of the clinical features of the disease are outbreak dependent with a different spectrum of clinical findings in one mini-outbreak compared with another, and with cases having similar clinical phenotypes clustering temporally.

So consider echo in any young child with persistent fever.

The term atypical or incomplete Kawasaki disease is used for cases without the required number of features. Whether this is the same disease or not is unclear; there will undoubtedly be some cases that overlap with other systemic vasculitides eg polyarteritis nodosa (PAN). In PAN, mucocutaneous changes are uncommon, whereas renal disease is common. Gall bladder hydrops appears to be unique to Kawasaki’s. On the other hand, having a rigid case definition is perhaps unhelpful since incomplete cases are often seen, particularly in infants, and are associated with a delay in diagnosis and worse prognosis. Under the age of 3 months, the majority of cases with coronary aneurysms have atypical presentations.

McCrindle AHA guideline suggest incomplete KD should be diagnosed where:

Differential diagnosis

Investigations mainly help exclude alternative diagnoses. Infection may have triggered KD so may need to treat for both – antibiotics if concern – get cultures. Typically with the disease itself test results simply indicate systemic inflammation and can be useful for monitoring response to treatment. Hence there are usually elevated white cells, platelets, ESR and CRP, ferritin/coag (MAS?), troponin (myocardial involvement?), D-dimers, LDH. Liver function tests are often mildly deranged. Low sodium and albumin suggest vascular leak. The ECG may have PR interval changes, and ST segment or T wave changes. Echocardiography (ideally within 2 weeks of onset of fever but as soon as possible) may reveal dilated, ectatic coronary arteries or frank aneurysms.

Consider CXR, Abdo USS (incl gall bladder).

Treatment

SPARN 2024 guidelines (based on AHA) advises taking serum for storage if possible, prior to IVIG. Refer for echo within 1-2 days assuming normal ECG and CXR. Admit under Infectious diseases or Rheumatology unless cardiomegaly, abnormal ECG, heart failure or giant aneurysms.

As with Eleftheriou (2013) guidelines, methylprednisolone in addition to IVIG/aspirin if high risk viz infants, severe inflammation (CRP>100, liver dysfunction, hypoalbuminaemia, anaemia), shock or HLH, evolving anuerysms/ectasia, failed IVIG – consider if thrombocytopaenia, late presentation). Infliximab is included as an option for resistant or recrudescent disease. Of course, diagnosis should be reconsidered if response to treatment is poor.

Standard treatment is with intravenous immunoglobulin (IVIG) 2g/kg over 12 hours, ideally within the first 7-10 days of the illness, and with aspirin (high initial dose 30-50 mg/kg/day in 4 divided doses orally during the acute phase – AHA still recommends before switching to low dose but insufficient evidence of benefit). This combination reduces the risk of aneurysm formation from 25% to 9%. Most will respond to a single dose, but about 20% will require a second dose. Add steroids if not given already and consider second dose if persistent fever and/or failure of CRP to fall at least 50% within 48 hours. Of these, only a half will then defervesce.

IVIG side effects – fever, headache, joint pain, aseptic meningitis, BBV, allergic reaction (?), raised ESR. Remember to defer immunisations for 3 months.

Once defervescence has occurred, the aspirin dose can be reduced to an anti-platelet dose of 3-5mg/kg/day (max 75mg). Aspirin is stopped after 6 weeks unless aneurysms found.

Duration of fever is the most powerful predictor of poor coronary outcome (one additional day of fever increasing the odds of aneurysm development by 3-5x). Delayed diagnosis is usually a reflection of slow evolution of criteria rather than atypical presentation – in that study, diagnosis after 10 days had a 2.8x higher risk of aneurysms (although they also had higher platelet counts). [Pediatrics. 115(4):e428-33, 2005. PMID 15805345]

Methylprednisolone treatment is 0.8mg/kg BD IV for 5-7 day or until CRP normal, followed by Prednisolone 2mg/kg weaning over 2-3 weeks. Other regimes are Methylpred 10-30mg/kg IV OD for 3 days followed by prednisolone.

In Europe steroids reserved for worse cases – but by epidemiology, all European cases could be considered high risk?? 39% of under 1yrs had coronary aneurysms (BPSU study). Europe Kawasaki trial in progress (KDCAAP) – Adding immediate corticosteroid treatment to standard of care IVIG and aspirin.

Scoring

Several scorings systems have been developed to predict IVIG resistance and poor outcome. Kobayashi criteria used to predict IVIG failure (5+ points), but more sensitive in Japanese populations – just 33% in Non-Japanese, with 87% specificity:

  • Age<12 months (2 points)
  • Fever <=4 days (1 point)
  • Na<=133 (2 points)
  • ALT>=100 (1 point)
  • Plts <300 (1 point)
  • CRP>10 (1 point)
  • >80% neutrophils (2 points)

Echo

ECG and echo should be done as soon as possible but should not delay treatment. Urgent if heart failure, cardiomegaly on CXR or ECG abnormalities. If first echo is normal and CRP normal after 1 week, repeat scans recommended at 2 and 6-8 weeks. But chase cardiology to repeat early if diagnosis unclear.

Those with Z score more than 10 (“large”) have 25% risk of coronary event within 10yrs (girls), 50% (boys)!

Most aneurysms will resolve over time, unless they are giant (>8mm). Serial echocardiography should be done to monitor resolution. Evidence of subacute chronic vasculitis for months (post-mortem cases) so move now to infliximab treatment etc after initial immunosuppression.

Warfarin should be considered for giant aneurysms, with initial heparinization to prevent paradoxical thrombosis, although its potential for complications in young children is significant. Stress testing and angiography may be appropriate. Aspirin can be discontinued if aneurysms resolve, but it is likely that the atherosclerosis risk remains high and life long follow up to address other risk factors is sensible.

Mortality in the UK has been as high as 3.7%, but is much lower in Japan.

[2020 ArchDisChild Ed and Practice Kelly]

[2017 AHA guidelines]

[Eleftheriou Arch Dis Child 2014;99:74–83, J Paed and Child Health 49 (2013) 614–623]

UK vaccine schedule

Changes depending on availability (and cost) of new vaccines, changes in epidemiology.  And levels of public acceptance!  Recommendations made by JCVI (Joint committee on vaccines and immunization).  Most recent change is introduction of MenB (Bexsero).

  • At, 2, 3 and 4 months, a 5 in 1 vaccine containing diphtheria/tetanus/pertussis with polio and Hib is given (Pediacel).
  • Prevnar (pneumococcal conjugate, PCV-13) is given at 2 and 4 months with a booster at 12-13 months
  • MenC now given at 3 months only (other 2 doses dropped), in between Prevnar, with a booster at MMR time.
  • Oral rotavirus vaccine is now given at 2 and 3 months.
  • Bexsero (MenB) vaccine is given at 2 and 4 months, with booster at 12-13 months.

At 12-13 months, MMR – along with boosters of Hib/MenC (Menitorix), Prevnar and MenB

Annual nasal influenza vaccines are being phased in over next few years, currently all primary school and ages 2-4yrs.  Will eventually be all up to 16.

At 3yrs 4 months- 5yrs, preschool booster – DTP/Polio (Repevax, no Hib) and MMR again.

At 13yrs, BCG has been dropped as a universal vaccine. There is now a booster of MenC, along with Tetanus, diphtheria (low dose) and polio (no pertussis, Revaxis).

Girls between 12 and 14yrs get 2 doses of HPV vaccine, at least 6/12 apart.

Over 65s get scheduled PPV (pneumococcal polysaccharide, once) and annual influenza.

Over 70s get a single Shingles vaccine.

The acellular pertussis vaccine (3 or 5 antigens cf 3000 in whole cell) is associated with less reactions (but less effective and immunity shorter lasting); IPV (injectable) polio vaccine has same efficacy as OPV (oral, live, Sabin, herd immunity), plus no vaccine associated disease.

These newer vaccines have fewer reactions, and do not contain thiomersal. Not that there’s any evidence against mercury, but plan to eliminate it has been in place for several years.

There was also an issue with loss of Hib efficacy when using 3 in 1 DTP for primary immunizations, which is not seen with Pediacel.

No individual boosters for tetanus are available. Choice is between Infanrix (DTaP), Repevax or Revaxis.

Instead of BCG for all adolescents, risk factor approach introduced: BCG will be offered to all infants in health boards with incidence over 40/10 000 (none in Scotland), and to those with parent or grandparent from high incidence area.

Rhinitis QOL

You can just use generic SF-36 questionnaire, statistically significant differences between patients and controls were observed in seven of nine dimensions in the SF-36 questionnaire. Or RQLQ score (mini-form also available). (J Allergy Clin Immunol 1997;99:S815-9.) SF-36 particuarly highlights mental adverse effects, RQLQ highlights sleep disturbance.

Quality-of-life parameters measured by the RQLQ questionnaire:

  • Sleep – Lack of a good night’s sleep, Wake during the night, Difficulty getting to sleep
  • Non-hay-fever symptoms – Tiredness, Fatigue, Worn out, Reduced productivity, Poor concentration, Thirst, Headache
  • Practical problems -Need to blow nose repeatedly,Need to rub nose/eyes,Inconvenience of having to carry tissues or handkerchief
  • Nasal symptoms -Stuffy/blocked,Sneezing,Runny,Itchy
  • Eye symptoms – Itchy, Watery,  Swollen,  Sore
  • Emotions – Irritable,  Frustrated,  Impatient or restless, Embarrassed by nose/eye symptoms
  • Activities eg  Bicycling Cooking Dancing Doing home maintenance Doing housework Gardening Eating out Jogging, exercising, or running Attending public events Driving a car Watching TV or a movie Singing Mowing the lawn Playing with pets Doing regular social activities Talking (public speaking) Studying or doing homework Taking a test or quiz Visiting friends or relatives Going for a walk Having sexual intercourse Carrying out activities at work Reading Playing sports

Juniper and Guyatt